Navigating Renin-Angiotensin System Inhibitors in Patients with Declines in eGFR

What is it about?

Two articles published in this month's issue of JASN provide important insights into how to interpret and navigate changes in laboratory values after starting renin-angiotensin system inhibitors, a class of blood pressure medications that are the cornerstone of treatment in patients with chronic kidney disease. Together, the articles suggest that decline in kidney function after starting this class of medication is an important indicator of increased risk of kidney failure in the future, but that restarting these medications after they have been stopped lowers the risk of death in most people.

Featured Image